We are live on
!
Find out more
State Street SPDR S&P Biotech ETF
123 hedge funds and large institutions have $1.6B invested in State Street SPDR S&P Biotech ETF in 2014 Q2 according to their latest regulatory filings, with 22 funds opening new positions, 26 increasing their positions, 56 reducing their positions, and 29 closing their positions.
New
Increased
Maintained
Reduced
Closed
16.59% more ownership
Funds ownership: 387.44% → 404.03% (+17%)
1% less capital invested
Capital invested by funds: $1.62B → $1.6B (-$23.4M)
6% less funds holding
Funds holding: 131 → 123 (-8)
24% less first-time investments, than exits
New positions opened: 22 | Existing positions closed: 29
50% less funds holding in top 10
Funds holding in top 10: 4 → 2 (-2)
54% less repeat investments, than reductions
Existing positions increased: 26 | Existing positions reduced: 56
78% less call options, than puts
Call options by funds: $10.7M | Put options by funds: $48.9M
Holders
123
Holders Change
-8
Holders Change %
-6.11%
% of All Funds
3.54%
Holding in Top 10
2
Holding in Top 10 Change
-2
Holding in Top 10 Change %
-50%
% of All Funds
0.06%
New
22
Increased
26
Reduced
56
Closed
29
Calls
$10.7M
Puts
$48.9M
Net Calls
-$38.2M
Net Calls Change
-$91.1M
Top Buyers
| 1 |
Goldman Sachs
New York
|
+$96.6M |
| 2 |
U
UBS
Zurich,
Switzerland
|
+$38.2M |
| 3 |
SCM
Sandler Capital Management
New York
|
+$17.9M |
| 4 |
Barclays
London,
United Kingdom
|
+$13.7M |
| 5 |
Morgan Stanley
New York
|
+$9.46M |
